## Quarterly Industry Update

As of June 30, 2016 **Industry: Monoclonal Antibodies** 




### Industry Summary

Cogent Valuation identified Monoclonal Antibodies publicly traded companies, IPOs, and recent M&A transactions within the Monoclonal Antibodies industry, which provides a basis for market and transaction pricing that can be used by your firm in estimating market sentiment and its impact on your firm's value. Over the last year since June 30, 2015, the median 52-week share price return of the Monoclonal Antibodies industry was -52.0%. Between June 30, 2014 and June 30, 2016, the median EV/Revenue multiple decreased from 8.0 to 2.1. This industry is not profitable and all other valuation multiples based on profitability metrics were not meaningful.

Comparable Public Company Key Statistics												
Median 52-Week Return	-52.0%	Median EV/Revenue Multiple			2.1x	M	leturn	-26.6%				
Comparable Public Company Market Price Returns As of June 30, 2016												
	YTD	3 Month	1 Year	2 Year	3 Year	5 Year	2015	2014	2013	2012	2011	
Alder Biopharmaceuticals Inc.	-24.4%	2.0%	-52.9%	11.5%	N/A	N/A	13.5%	N/A	N/A	N/A	N/A	
AVEO Pharmaceuticals, Inc.	-23.7%	4.5%	-44.8%	-27.5%	-27.3%	-45.8%	50.0%	-54.1%	-77.3%	-53.2%	17. <b>6</b> %	
Celldex Therapeutics, Inc.	-72.0%	16.1%	-82.6%	-48.1%	-34.5%	4.3%	-14.1%	-24.6%	260.8%	158.1%	-36.9%	
Halozyme Therapeutics, Inc.	-50.2%	-8.9%	-61.8%	-6.5%	2.8%	4.5%	79.6%	-35.6%	123.4%	-29.4%	20.1%	
Immunomedics Inc.	-24.4%	-7.2%	-42.9%	-20.3%	-24.7%	-10.6%	-36.0%	4.3%	57.5%	-12.3%	-7.0%	
Infinity Pharmaceuticals, Inc.	-83.1%	-74.8%	-87.9%	-67.7%	-56.5%	-30.6%	-53.5%	22.3%	-60.5%	295.9%	<b>49</b> .1%	
Lpath Inc.	<b>859.9</b> %	-16.3%	-43.6%	-80.2%	-67.2%	-53.1%	-91.9%	-33.8%	-15.6%	-39.4%	33.7%	
Omeros Corporation	-33.1%	-31.4%	-41.5%	-22.2%	27.8%	20.6%	-36.5%	119.5%	117.5%	31.4%	-52.1%	
OncoMed Pharmaceuticals, Inc.	-45.4%	21.8%	-45.3%	-27.3%	N/A	N/A	3.6%	-26.3%	N/A	N/A	N/A	
PDL BioPharma, Inc.	-11. <b>3</b> %	-5.7%	-51.2%	-43.0%	- <b>2</b> 5. <b>9</b> %	-11.8%	-54.1%	-8.6%	1 <b>9.9</b> %	13.5%	-0.5%	
Peregrine Pharmaceuticals, Inc.	-68.9%	-13.4%	-72.2%	-56.0%	-34.4%	-27.8%	-15.8%	0.0%	5.3%	28.2%	-55.2%	
Repligen Corporation	-3.3%	2.0%	-33.7%	9.6%	49.2%	49.7%	42.9%	45.2%	117. <b>2</b> %	81.0%	-26.0%	
Sorrento Therapeutics, Inc.	-35.7%	4.1%	-68.2%	-8.9%	-8.2%	-5.7%	-13.5%	24.3%	116.0%	-25.0%	-66.7%	
XOMA Corporation	-58.5%	-28.7%	-85.8%	-65.3%	-46.6%	-25.2%	-63.0%	-46.7%	180.4%	108.7%	-77.6%	
Median of Industry Public Companies	-34.4%	-6.5%	-52.0%	-27.4%	-26.6%	-11.2%	-15.0%	-8.6%	86.8%	20.9%	-16.5%	

(Multiple year periods are calculated as the average annual return.)



#### Median Public Company Multiples of the Monoclonal Antibodies Industry

Date:	6/30/2014	9/30/2014	12/31/2014	3/31/2015	6/30/2015	9/30/2015	12/31/2015	3/31/2016	6/30/2016
EV/Revenues Multiple	8.0x	6.7x	8.0x	5.9x	5.1x	5.8x	3.1x	1.5x	2.1x

This industry research is provided at no charge to Cogent Valuation's clients. Research or detailed information not covered in this report can be obtained for a fee. Contact Steven Kam at 415-392-0888 for additional information or questions in connection with this research report. Copyright © 2016 Cogent Valuation. All Rights Reserved.

Dec 2015

Mor 2016

Jun 2016

Gross Cash Flow

# **Quarterly Industry Update**

As of June 30, 2016 Industry: Monoclonal Antibodies



### Industry Initial Public Offerings (dollars in millions, except share prices)

non not manifest N/A not multiphie										
Median of All IPOs		nm	nm	\$53.8	\$64.9	\$8.3	\$3.5	(\$18.1)	(\$32.5)	(\$15.8)
11/13/2014	FibroGen, Inc.	\$18.00	8.1	\$145.8	\$344.4	\$114.1	\$133.9	(\$22.6)	(\$35.7)	(\$18.1)
12/10/2014	ALTEOGEN Inc.	\$23.53	0.9	\$21.2	\$5.4	\$1.1	\$3.7	\$1.6	\$1.3	\$1.6
2/2/2016	BeiGene, Ltd.	\$24.00	6.6	\$158.4	\$135.6	\$20.6	\$5.5	(\$35.3)	(\$33.6)	(\$33.8)
3/22/2016	Corvus Pharmaceuticals, Inc.	\$15.00	4.7	\$70.5	\$98.5	\$0.0	\$0.0	(\$13.6)	(\$31.3)	(\$13.5)
4/14/2016	GeNeuro SA	\$14.63	2.5	\$37.1	\$22.6	\$0.2	\$2.8	(\$4.7)	(\$4.9)	(\$4.6)
<u>5/12/2016</u>	<u>Company Name</u> Oncobiologics, Inc.	\$6.00	<u>5.8</u>	\$35.0	\$31.3	\$15.5	\$3.3	(\$56.6)	(\$59.4)	(\$54.4)
Offer Date		Offer Price	Shares Offered	Amount Raised	Total Assets	Debt	LTM Revenues	LTM EBITDA	LTM Net Income	LTM Cash Flows

nm: not meaningful, N/A: not applicable

#### Recent Merger and Acquisition Transactions for a Majority Stake (dollars in millions)

Transaction Date	<u>Target</u>	<u>Acquirer</u>	Transaction Size	<u>% Bought</u>	LTM Revenues	<u>EV/Revenues</u>			Size	e of M8	A Transa	octions
6/30/2016	EPIRUS Biopharmaceuticals	Polpharma SA Pharmaceutical	\$3.5	100%	N/A	N/A		<b>7</b> r				
5/31/2016	Effimune SA	OSE Pharma SA	\$34.4	100%	N/A	N/A		6				
4/18/2016	Biotie Therapies Corp.	Acorda Therapeutics, Inc.	\$341.6	100%	\$4.1	62.7x	suo	5				
1/22/2016	Dyax Corp.	Shire Pharmaceuticals	\$5,886.3	100%	\$97.5	57.2x	sacti	4				
1/8/2016	Open Monoclonal Tech.	Ligand Pharmaceuticals	\$178.0	100%	N/A	N/A	: Tran	3				
11/23/2015	AxioMx Inc.	Abcam Plc	\$45.2	100%	N/A	N/A	Number of Transactions	2				
10/30/2015	BioNovion B.V.	Aduro Netherlands	\$61.3	100%	N/A	N/A	Aumk N	1				
9/11/2015	PacificGMP, Inc.	Abzena Inc.	\$8.4	100%	\$3.0	2.8x	-	0				
6/1/2015	X-BODY, Inc.	Juno Therapeutics Inc.	\$42.8	100%	N/A	N/A		-	1510	2 <sup>10</sup> 50	250 0	00 75,00°
3/12/2015	KBI Biopharma Inc.	JSR Corporation; CMIC	\$100.0	100%	N/A	N/A			7	7	p-250 10	7 2
3/3/2015	SuppreMol GmbH	Baxter International Inc.	\$223.9	100%	N/A	N/A					7	
9/23/2014	CFR Pharmaceuticals	Abbott Investments	\$2,659.3	73%	\$782.3	4.3x			LTN	/I Rever	nues Rep	orted
4/30/2014	Shanghai PrimeGene	R&D Systems China	\$18.8	100%	\$4.0	4.7x		7 [				
12/31/2013	Santarus, Inc.	Salix Pharmaceuticals	\$2,154.4	100%	\$337.8	5.9x	su	6				
2/8/2013	YM BioSciences Inc.	Gilead Sciences Inc.	\$482.9	100%	\$1.1	N/A	sactio	5				
8/2/2012	Human Genome Sciences Inc.	GlaxoSmithKline plc	\$3,674.4	100%	\$151.5	21.1x	Trans	4				
4/18/2012	Epitomics, Inc.	Abcam Plc	\$153.9	100%	\$24.7	6.2x	er of	3				
3/5/2012	Micromet, Inc.	Amgen Inc.	\$1,016.4	100%	\$21.9	39.1x	Number of Transactions	2				
2/10/2012	Inhibitex, Inc.	Bristol-Myers Squibb	\$2,579.0	100%	\$2.1	N/A	z	1				
5/24/2011	MitoSciences Inc.	Abcam Plc	\$6.0	100%	\$2.1	2.9x		Uŀ	25210	50	250	7 \$250
10/7/2010	ZymoGenetics, Inc.	Bristol-Myers Squibb	\$938.2	100%	\$162.8	4.5x			~	7510	7 550.250	1*
Median of the 21 M&A Transaction Targets			\$178.0	100%	\$21.9	5.9x						

### Definitions of Financial Terms Used in this Quarterly Industry Update:

Enterprise Value (EV): Market Value of Equity + Market Value of Debt - Cash

Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA): Profitability metric sometimes also referred to as operating profit or operating earnings.

Gross Cash Flows: Net Income + Depreciation and Amortization Expense

Latest Twelve Months (LTM): Financial information is as of the latest twelve months through the date of this Quarterly Industry Update.

**Disclosures and Limitations:** This research report is for informational and discussion purposes only. Information presented herein is not investment advice of any kind to any person and does not constitute a recommendation as to the purchase or sale of any interests or as to any other course of action. General, financial, and statistical information concerning the details of this report and related industry are from sources. Cogent Valuation believes to be reliable. Cogent Valuation has accurately reflected such information in this research report; however, Cogent Valuation makes no representation as to the sources' accuracy or completeness and has accepted this information without further verification. Neither all nor any part of the content of this report may be conveyed to the public through advertising, public relations, news, sales, mail, direct transmittal, or other media without the prior written consent of Cogent Valuation. Cogent Valuation's research is as of the date reported herein. Cogent Valuation has no affiliation with any of the companies comprising the industry used as a basis for research in this report, nor does Cogent Valuation hold any investments in the companies listed herein. The content of this report IS NOT TO BE USED OR CONSIDERED UNDER ANY CIRCUMSTANCE BY ANYONE AS INVESTMENT ADVICE. This industry research is provided at no charge to Cogent Valuation's clients. Research or detailed information not covered in this report can be obtained for a fee. Contact Steven Kam at 415-392-0888 for additional information or questions in connection with this research report. Copyright © 2016 Cogent Valuation. All Rights Reserved.